Marshall Edwards, Inc has been granted an Investigative New Drug (IND) approval by the United States Food and Drug Administration to undertake clinical studies with triphendiol as a chemosensitising agent in combination with gemcitabine. This approval will enable a phase-Ib study of triphendiol in combination with gemcitabine in patients with unresectable, locally advanced or metastatic pancreatic and bile duct cancers.

Triphendiol (NV-196) is an investigational drug in the Marshall Edwards, Inc, oncology drug pipeline, currently being developed as an orally-delivered chemosensitizing agent, intended for use in conjunction with standard chemotoxic anti-cancer drugs for the treatment of late stage pancreatic cancer, cholangiocarcinoma, and melanoma.

Marshall Edwards is a specialist oncology company focused on the clinical development of novel anti-cancer therapeutics.